Related Experiment Video

Updated: Nov 3, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

393

EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation

Ying Li1,2, Yongwen Li1,2, Hongbing Zhang2

  • 1School of Chemical Engineering and Technology, Tianjin University, Tianjin, 300072, China.

BMC Pulmonary Medicine
|June 6, 2021
PubMed
Abstract

Insights

Aberrant echinoderm microtubule-associated protein-like-4 anaplastic lymphoma kinase (EML4-ALK) expression activates the JAK2-STAT pathway, driving non-small cell lung cancer (NSCLC) development. This pathway is crucial for NSCLC transformation and offers potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • The echinoderm microtubule-associated protein-like-4 anaplastic lymphoma kinase (EML4-ALK) fusion gene is found in some non-small cell lung cancer (NSCLC) patients.
  • These patients often show positive responses to anaplastic lymphoma kinase (ALK) inhibitors.

Purpose of the Study:

  • To investigate the molecular mechanisms by which EML4-ALK drives NSCLC transformation.
  • To characterize the role of the JAK2-STAT signaling pathway in EML4-ALK-induced oncogenesis.

Main Methods:

  • Cell lines (HEK293, NIH3T3, H2228) were transfected with EML4-ALK or control vectors/siRNA.
  • Cell viability, proliferation, and apoptosis were assessed using CCK-8, EdU assays, and flow cytometry.
  • Gene expression profiling, qPCR, Western blotting, co-immunoprecipitation, and immunofluorescence were employed to analyze pathway activation and protein interactions.

Main Results:

  • EML4-ALK expression activated the JAK2-STAT pathway, including phosphorylation of JAK2 and STAT proteins (STAT1, STAT3, STAT5, STAT6).
  • Activated JAK2 and STAT6 colocalized with ALK in cells expressing EML4-ALK.
  • EML4-ALK knockdown reduced cell proliferation and increased apoptosis, while its overexpression in normal cells increased viability. Inhibitor studies confirmed the role of ALK and JAK-STAT signaling.

Conclusions:

  • Aberrant EML4-ALK expression is a key driver of NSCLC.
  • Activation of the JAK2-STAT signaling pathway by EML4-ALK is essential for NSCLC development.
  • Targeting the JAK2-STAT pathway may offer therapeutic strategies for NSCLC patients with EML4-ALK fusions.
Keywords:
EML4-ALKJAK2-STAT pathwayNon-small cell lung cancerTransformation

More Related Videos

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

3.9K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

591

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.6K